Biosimilars: Can They Break Through?

The report, presented by the Alliance for Patient Access (AfPA) and titled “Biosimilars: Can They Break Through?” will include discussion on the policy issues surrounding biosimilars in the United States. Topics will include:

• Given pending FDA regulations, what are the obstacles in getting biosimilars to market?
• What are the concerns surrounding the labeling or prescriber information, and why is the issue of naming so hotly contested?

For more information, visit POLITICO: http://www.politico.com/events/2015/11/pro-health-care-report-biosimilars-can-they-break-through-215763